Successful drug discovery is founded on “𝘪𝘯-𝘴𝘪𝘭𝘪𝘤𝘰 𝘧𝘪𝘳𝘴𝘵” approaches, such as using GOLD for virtual screening and predicting protein-ligand interactions. 

On May 13, join BIOVIA and CCDC - The Cambridge Crystallographic Data Centre as we present how GOLD’s advanced algorithms enable accurate and efficient virtual screening, lead optimization and structure-based drug design — driving innovation in small molecule therapeutics discovery on the collaborative #3DEXPERIENCE® cloud platform.

Learn more and register here: http://go.3ds.com/598Y.